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Background: The ﬁndings of currently available studies are not consistent with regard to the association
between the risk of cancer and ginseng consumption. Therefore, we aimed to evaluate this association by
conducting a meta-analysis of different studies.
Methods: To systematically evaluate the effect of ginseng consumption on cancer incidence, six data-
bases were searched, including PubMed, Ovid Technologies, Embase, The Cochrane Library, China Na-
tional Knowledge Infrastructure, and Chinese VIP Information, from 1990 to 2014. Statistical analyses
based on the protocol employed for a systematic review were conducted to calculate the summary
relative risks (RRs) and 95% conﬁdence intervals (CIs).
Results: We identiﬁed nine studies, including ﬁve cohort studies, three case-control studies, and one
randomized controlled trial, evaluating the association between ginseng consumption and cancer risk;
these studies involved 7,436 cases and 334,544 participants. The data from the meta-analysis indicated a
signiﬁcant 16% lower risk of developing cancer in patients who consumed ginseng (RR ¼ 0.84, 95%
CI ¼ 0.76e0.92), with evidence of heterogeneity (p ¼ 0.0007, I2 ¼ 70%). Stratiﬁed analyses suggested that
the signiﬁcant heterogeneity may result from the incidence data for gastric cancer that were included in
this study. Publication bias also showed the same result as the stratiﬁed analyses. In addition, subgroup
analyses for four speciﬁc types of cancer (colorectal cancer, lung cancer, gastric cancer, and liver cancer)
were also performed. The summary RRs for ginseng intake versus no ginseng consumption were 0.77 for
lung cancer, 0.83 for gastric cancer, 0.81 for liver cancer, and 0.77 for colorectal cancer.
Conclusion: The ﬁndings of this meta-analysis indicated that ginseng consumption is associated with a
signiﬁcantly decreased risk of cancer and that the effect is not organ speciﬁc.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer imposes a global threat to public health. According to the
Global Cancer Statistics estimates, there were about 14.1 million
new cancer cases and 8.2 million cancer deaths in 2012 [1].
Importantly, these numbers have rapidly increased with increased
population growth and environmental pollution. Malignancy re-
sults from complex interactions among multiple genes, the intra-
cellular environment, and neighboring tissues [2]. The basic theory
of tumorigenesis suggests that the process starts with a normal cellg Delivery System of Chinese Mater
n, 120 Suzhi Road, Suqian, Jiangsu
Jia), xiaobinjia_nj@126.com (X.-b. J
ht  2015, The Korean Society of G
d/4.0/).that is transformed through the activation of proto-oncogenes and
the suppression of tumor suppressor genes. After the trans-
formation, the cell does not behave like a normal cell, but instead
begins to exhibit the properties of a cancer cell. These transformed
cells acquire the capability to proliferate uncontrollably through
self-sufﬁciency in growth signals and are insensitive to antigrowth
signals. In addition, they are able to evade apoptosis, eventually
resulting in tumor growth. As the tumor continues to develop, its
growth is aided by the development of new blood vessels that
provide it with nutrients, thereby allowing it to sustain itself andia Medica, Jiangsu Provincial Academy of Chinese Medicine, 100 Shizi Road, Nanjing,
223800, China.
ia).
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
Fig. 1. Flowchart of study selection. ICTRP, International Clinical Trials Registry Platform; WHO, World Health Organization.
J Ginseng Res 2016;40:269e277270even invade other tissues, resulting in metastasis that is ultimately
lethal [2e5].
Chemoprevention is deﬁned as the use of natural, synthetic, or
biological agents to prevent, suppress, and reverse the carcinogenic
progression. It is ideally effective in prevention of the disease and
should be nontoxic. Chemoprevention is characterized by the
disruption of, or at least the delay of, multiple pathways and pro-
cesses in the three stages of carcinogenesis, namely, initiation,
promotion, and progression [6,7]. Chemicals or biomolecules that
inhibit the initiation stage are necessary for the preservation of
DNA [8,9]. In contrast to compounds that preserve DNA, com-
pounds that affect the later stages of carcinogenesis (promotion
and progression) are known for their ability to decrease the pro-
liferative capacity of initiated cells. They interfere with cancer cell
proliferation by downregulating the expression of the molecules
involved in signal-transduction pathways, such as nuclear factor
kappa-light-chain enhancer of activated B cells (NF-kB), mamma-
lian target of rapamycin, and signal transducer and activator of
transcription 3, and by inhibiting cytochrome P450 enzymes that
modulate signal transduction to hormone-responsive elements
[10]. In addition, suppressing agents are likely to reduce or delay
the ability of cancer cells to acquire metastatic properties by pro-
moting pathways leading to apoptosis [11] and inhibiting pathways
leading to angiogenesis, epithelial mesenchymal transition, inva-
sion, and dissemination [12].Traditional herbal medicine used for thousands of years is ad-
vantageous in maintaining a balanced health status and help pre-
vent further diseases in a safe and effectivemanner. Ginseng (Panax
ginseng Meyer) is widely used and has been included in pharma-
copoeias in China, Japan, Germany, France, Austria, and the United
Kingdom. It is widely available as an over-the-counter drug and also
commonly used as an adjuvant to increase human immunity
[13,14]. Furthermore, the protective effect of ginseng in cancer
chemoprevention has been shown by extensive laboratory and
preclinical studies [15]. Ginseng is chemoprophylactic and often
acts on its cellular and molecular targets through various signaling
pathways, thereby inhibiting the tumor by regulation of the cell
cycle, induction of apoptosis, and inhibition of angiogenesis and
invasion [16,17]. The anticancer effects of ginseng involve modu-
lation of diverse signaling pathways, including regulation of cell
proliferation mediators (cyclin-dependent kinases and cyclins),
growth factors (c-myc, epidermal growth factor receptor, and
vascular endothelial growth factor), tumor suppressors (p53 and
p21), oncogenes (MDM2), cell death mediators [B-cell lymphoma 2
(Bcl-2), B-cell lymphoma-extra large (Bcl-xL), X-linked inhibitor of
apoptosis protein (XIAP), caspases, and death receptors], inﬂam-
matory response molecules (NF-kB and cyclooxygenase-2), and
protein kinases (c-Jun N-terminal protein kinase, Akt, and adeno-
sine monophosphate-activated protein kinase) [18]. During the
past decade, although a series of epidemiologic studies had
Table 1
Characteristics of studies included in the meta-analysis
Study Study design Study population Study period Cases/control or
cohort or RCT
Ginseng type and
consumption
RR (95% CI) Adjustments
Yun and Choi
1990 [26]
Case-control
study
Seoul, Korean 1987e1988 905/905
Men 48%
Ginseng 562/905 vs.
674/905
0.83 (0.78,0.89) Demographic characteristics (age, marital status, education,
occupation, and income), lifestyle (cigarette smoking,
alcohol consumption, and others), and ginseng
consumption
Yun and Choi
1995 [28]
Case-control
study
Seoul, Korean 1988e1990 1,987/1,987
Men 54%
Ginseng 1,066/1,987 vs.
1,382/1,987
0.77 (0.73, 0.81) Sociodemographic characteristics, lifelong occupational
history, smoking habits, drinking habits, and ginseng
intakeGinseng (colorectal cancer)
63/118 vs. 86/118
0.73 (0.60, 0.90)
Ginseng (lung cancer)
156/276 vs. 195/276
0.80 (0.70, 0.91)
Ginseng (gastric cancer)
158/300 vs. 224/300
0.71 (0.62, 0.80)
Ginseng (liver cancer)
156/264 vs. 179/264
0.79 (0.70, 0.90)
Yun and Choi
1998 [21]
Cohort study Seoul, Korean 1987e1992 137/4,450
age was over
40 yr, followed
for 5 yr
Men 51%
Ginseng 75/137 vs.
3,167/4,450
0.77 (0.66, 0.90) Demographic characteristics, lifelong occupation, smoking
and drinking habits, history of diseases, ginseng intake,
etc.Ginseng (lung cancer)
10/24 vs. 3,167/4,405
0.59 (0.36, 0.94)
Ginseng (gastric cancer)
19/42 vs. 3,167/4,450
0.64 (0.46, 0.89)
Ginseng (liver cancer)
10/14 vs. 3,167/4,450
1.00 (0.72, 1.40)
Yun et al 2010
[29]
Randomized
controlled trial
Hangzhou, Chinese 1997e2008 325/318
age was between
40 and 69 yr with
chronic atrophic
gastritis
1 g of ginseng
every wk for
3 yr and followed
up for 8 yr
Men 61%
Red ginseng extract 8/24 vs.
317/616
0.65 (0.37, 1.15) Demographic characteristics, lifelong occupation, smoking
and alcohol drinking patterns, history of diseases, and
history of ginseng intakeGinseng (colorectal cancer)
1/2 vs. 324/641
0.99 (0.25, 3.96)
Ginseng (lung cancer)
2/8 vs. 323/635
0.49 (0.15, 1.64)
Ginseng (gastric cancer)
3/6 vs. 322/637
0.99 (0.44, 2.21)
Ginseng (liver cancer)
1/2 vs. 324/641
0.99 (0.25, 3.96)
Satia et al 2009
[23]
Cohort study Western
Washington
State, American
2000e2007 665/76,460
age was between
50 and 76 yr,
followed for a mean
of 5.0 y at least once a
wk for a yr
Ginseng (colorectal cancer)
29/428 vs. 6,309/76,084
0.82 (0.57, 1.16) Duration in yr, frequency in d/wk, and usual dose
of various supplements, including multivitamins,
individual vitamin and mineral supplements, other
mixtures, and herbal and specialty products
Ginseng (lung cancer)
43/665 vs. 6,322/76,460
0.78 (0.56, 1.05)
Kamangar et al
2007 [22]
Cohort study Shanghai, Chinese 1997e2004 21,318/52,134
Women aged
between 40 and 70 yr
followed for 4 yr
Ginseng (gastric cancer)
56/153 vs. 21,318/73,452
At least ﬁve times a yr
in the past 3 yr
1.26 (1.02, 1.55) Demographic characteristics, education and income,
lifestyle and habits, diet, taken ginseng, and several other
factors
Rebbeck et al
2007 [27]
Case-control
study
Philadelphia and
Delaware Counties
in Pennsylvania;
Camden County in
New Jersey,
American
1999e2002 949/1,524
Women aged
between 50 and 79 yr
Ginseng (breast cancer)
72/949 vs. 164/1,524
0.71 (0.54, 0.92) Demographic characteristics; family history of breast,
endometrial, and ovarian cancer; contraceptive history;
fertility history; menstrual and menopausal history;
medical history; detailed gynecologic screening history;
use of exogenous hormones; and use of other
medications
Use in European Americans
41/677 vs. 84/905
0.65 (0.46, 0.94)
Use in African Americans
31/272 vs. 80/619
0.88 (0.60, 1.30)
At least three times a wk
for 1 mo or more any time
(continued on next page)
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J Ginseng Res 2016;40:269e277272indicated that ginseng consumption affects cancer incidence, the
results of the studies are inconsistent. Therefore, a quantitative
analysis of the associations between ginseng consumption and risk
of cancer was necessary to expound the existing inconsistency in
the literature.
Thus, a meta-analysis aimed at reviewing and summarizing the
relationship between ginseng consumption and risk of cancer was
performed, and different relative risk (RR) ratios of cancer were
determined by performing subgroup analyses.
2. Materials and methods
2.1. Search strategy
We conducted a literature search for relevant articles in
PubMed, Ovid Technologies, Embase, Cochrane Library, China Na-
tional Knowledge Infrastructure, and Chinese VIP Information for
published papers from 1990 to July 2014 using the following search
terms without language restrictions: “ginseng,” “fresh ginseng,”
“white ginseng,” “red ginseng,” “ginseng supplement,” “ginseng or
fresh ginseng or white ginseng or red ginseng or ginseng supple-
ment,” “Neoplasms” (Mesh), “randomized controlled trial,”
“cohort,” “case control,” “randomized controlled trial or cohort or
case control,” “ginseng or fresh ginseng or white ginseng or red
ginseng or ginseng supplement and neoplasms (Mesh) and ran-
domized controlled trial or cohort or case control.”
In addition, the reference lists of the selected articles were also
reviewed to identify other relevant articles. The research was
conducting by two authors on their own account.
2.2. Study selection
The following criteria were chosen to identify the studies for
this meta-analysis: studies comprising a randomized controlled
trial or observation study with the exposure factor being ginseng
intake, studies with risk of cancer being the end point of interest,
and studies in which risk estimates were reported. If data were
included more than once, the latest and complete research was
chosen.
2.3. Data extraction and quality assessment
The data were charted as follows: ﬁrst author, publication
year, study design, region, study period, case and control, ginseng
type and consumption, RR, and confounding factors of interest.
The included studies were independently evaluated by two au-
thors using the methodological quality assessment system in
RevMan 5.3. Discrepancies in evaluation were resolved by a third
author, and potential publication bias was examined using Begg’s
test. A linear regression approach was used to measure the
funnel plot asymmetry on the natural logarithm scale of the RR
ratios [19].
2.4. Statistical analysis
The main analyses were focused on the associations between
consumption of ginseng and cancer incidence. In addition, the RR of
lung cancer, colorectal cancer (cancer of the colon and rectum),
gastric cancer (cancer of the stomach), and liver cancer was
determined in relation to ginseng consumptions in a subgroup
analysis.
All analyses were performed using Review Manager version 5.3
(Cochrane Collaboration software) and GRADE proﬁler version 3.6.
All p values are two-sided and p < 0.1 was considered signiﬁcant.
Fig. 2. Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies.
X. Jin et al / Ginseng consumption and risk of cancer 273Furthermore, the I2 index, a quantitative measure of inconsistency,
across studies was calculated [20].3. Results
3.1. Literature search
A ﬂowchart showing the study selection process is presented in
Fig. 1. In brief, a total of 4,619 publications and 18 studies that are
currently underway were identiﬁed. A total of 1,205 duplicates
were then removed. After screening the abstracts, we excluded the
duplicates, studies involving animal experiments and in vitro ana-
lyses, ingredient experimental studies, and reviews, etc. for not
meeting the inclusion criteria. After evaluating the full manuscripts
of the 46 potentially relevant articles, 37 potentially relevant
studies were excluded further because they were not related to the
to the risk ratio of cancer in humans and nonginseng use in
experimental group. Finally, nine studies were selected for analysis
[21e29].Fig. 3. Risk of bias summary: review authors’ judgments3.2. Study characteristics
The included studies were identiﬁed with regard to ginseng
consumption, and risk of cancer in this meta-analysis is presented
in Table 1. The eight observation studies, including ﬁve cohort
studies [21e25] and three case-control studies [26e28], were
published between 1990 and 2014. Only one randomized
controlled trial [29] was reported. Of these studies, four involved
research on lung cancer [21,23,28,29] and gastric cancer
[21,22,28,29], three assessed colorectal cancer [21,23,28,29] and
liver cancer [21,28,29], and one study each assessed prostate cancer
[24], hematologic malignancies [25], and breast cancer [27].
3.3. Quality assessment of the included studies
The Cochrane risk of bias tool was used to assess risk bias (Figs. 2
and 3). Because eight of the studies were observation studies, the
random sequence generation, allocation concealment, and blinding
of participants and personnel all showed high risk. Most of the
studies involved questionnaire analysis, and the participants wereabout each risk of bias item for each included study.
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J Ginseng Res 2016;40:269e277274diagnosed in different hospitals by randomized doctors. Therefore,
blinding of outcome assessment showed low risk. In addition,
outcome data loss was less than 20%, and therefore, incomplete
outcome data presented a low risk. Because the protocols of all the
trials were not accessible, selective reporting was generally unclear.
Therefore, the grading of recommendations assessment results is
shown with a low quality of evidence (Table 2).
3.4. Main analysis
A total of nine studies were included in this meta-analysis to
evaluate the association between ginseng intake and the risk of
cancer. There was a signiﬁcant 16% lower cancer risk associated
with ginseng consumption in comparison with the risk associated
with no ginseng consumption for all studies combined [RR ¼ 0.84,
95% conﬁdence interval (CI) ¼ 0.76e0.92], with evidence of het-
erogeneity (p ¼ 0.0007, I2 ¼ 70%) in Fig. 4.
3.5. Publication bias
There was no signiﬁcant combined publication bias in all
studies assessing the relationship between ginseng intake and
cancer incidence, as suggested by Begg’s rank correlation test in
Fig. 5 (p for Begg’s test was 0.596). However, the study by
Kamangar et al [22] may have had a high bias. When this study
was excluded from this meta-analysis, we observed a signiﬁcant
19% lower risk of developing cancer after ginseng consumption in
comparison with the risk without ginseng consumption
(RR ¼ 0.81, 95% CI ¼ 0.76e0.85), with low heterogeneity (p ¼ 0.20,
I2 ¼ 28%).
3.6. Subgroup and sensitivity analyses
The subgroup analyses according to the type of cancer are pre-
sented in Table 3. When the analyses were stratiﬁed by cancer site,
the summary RRs for ginseng intake versus no ginseng consump-
tion were 0.77 for lung cancer, 0.83 for gastric cancer, 0.81 for liver
cancer, and 0.77 for colorectal cancer. Evidence of heterogeneity
was observed only in the gastric cancer subgroup (Fig. 6). In addi-
tion, sensitivity analysis indicated that the summary estimates
(RR ¼ 0.81, 95% CI ¼ 0.76e0.85) showed low heterogeneity
(p ¼ 0.20, I2 ¼ 28%) when the study by Kamangar et al [22] was
excluded. Meanwhile, in the gastric cancer subgroup, the sensitivity
analysis also indicated that when the Kamangar et al [22] studywas
excluded, the summary estimates changed (RR ¼ 0.70, 95%
CI ¼ 0.62e0.79), with no signiﬁcant heterogeneity (p ¼ 0.59,
I2 ¼ 0%).
4. Discussion
The present meta-analysis, based on the latest published results,
is the ﬁrst quantitative systematic analysis of the association be-
tween ginseng consumption and cancer risk in 7,436 cases and
334,544 participants. The meta-analysis of the studies identiﬁed
indicated that ginseng consumption may be associated with a
reduced risk of cancer. We found substantial heterogeneity in the
association between ginseng consumption and cancer risk across
studies. This is not surprising given the variation in study designs
and characteristics of the study populations. However, the stratiﬁed
analysis by cancer type showed signiﬁcant heterogeneity only for
gastric cancer. It indicated that gastric cancer may be the major
source of heterogeneity. Furthermore, when we separated the
population in Shanghai, China [22] from others in Seoul, Korea
[21,28,29], the results indicated no signiﬁcant inverse association
between ginseng consumption and gastric cancer risk. Because the
Fig. 4. Meta-analysis of studies examining association between ginseng consumption and risk of cancer. CI, conﬁdence interval.
X. Jin et al / Ginseng consumption and risk of cancer 275chemical components of ginseng differ by region, the inclusion of
studies from different regions may have been responsible for the
heterogeneity. Moreover, the exposure factor may be greater,
because patient information obtained after diagnoses in an obser-
vation study could also result in systematic errors. However, the
fact that large numbers of cases and controls were involved in this
meta-analysis also means that the ﬁndings about association be-
tween ginseng consumption and the risk of cancer are more reli-
able. In addition, we found a signiﬁcant association between
ginseng intake and reduction of cancer incidence, which further
strengthened our result.
The basic mechanism of cancer development is now known to
result from an accumulation of genetic and epigenetic alterations in
cells [30]. Although diagnosis and treatment are the major strate-
gies for controlling cancer, the importance of cancer chemopre-
vention has gradually increased because advanced cancer is
difﬁcult to cure [31,32].
Ginseng, a famous traditional Chinese medicine, has been used
for thousands of years [33]. Its usefulness in cancer prevention
and therapy has been shown by extensive preclinical and epide-
miological studies [34e36]. The main active ingredients of
ginseng are often thought to be ginsenosides. The anticancer ef-
fects of ginseng involve diverse molecular mechanisms of action,
which in turn involve the regulation of most knownmodulators of
carcinogenesis [19]. Because ginsenosides cause tumor cell death
through various mechanisms, it may be difﬁcult for cells to
develop resistance to ginsenoside-induced death. Furthermore,Fig. 5. Begg’s funnel plot of ginseng consumption and risk of cancer incidence. RR,
relative risk; s.e., standard error.the ability of ginsenosides to kill tumor cells and relative non-
toxicity to normal cells make them attractive candidates for drug
development [37]. The diverse properties of ginseng are attrib-
utable to the diversity in both chemical structure and biological
activity.
The study by Kamangar et al [22] showed opposite effects. The
types of ginseng used by the participants in their studywere similar
to those used in other studies. However, the group and its extension
were selected from among patients whowere also referred to other
studies included in this meta-analysis. Therefore, the sex of the
patients included was signiﬁcantly different from others. The
prevalence of sex differences might have led to greater bias in this
group than in the general population because of the differences in
lifestyle and genetic constitution of female participants. Therefore,
further evaluation of the association between ginseng consumption
and sex may be needed to clarify ginseng’s role in cancer.
Several potential limitations of our meta-analysis should be
considered while interpreting the results. First, most of the studies
included were observational studies, and the presence of cohort
and case-control studies may have introduced confounding factors
and biases as a result of the different methods used in the studies.
Second, studies included were mainly conducted in Korea, China,
and the United States; therefore, the data should be extrapolated to
other populations with caution. Third, the apparent protective ef-
fect of ginseng against cancer may be also attributable to genetic
and other environmental factors. Finally, the articles included in
our meta-analysis were published in journals. Unpublished studies
and original data were not included. However, our meta-analysis
also has several strengths. In particular, it allowed us to directly
address the association between ginseng consumption and cancer
risk in humans, avoiding the uncertainties derived from the use of
animal data and mathematical models, and to assess the publicTable 3
Subgroup analyses of the risk ratio of different kinds of cancer
Group Number of
studies
Risk ratio (95%
conﬁdence interval)
pheterogeneity I
2, %
All 9 0.84 (0.76, 0.92) 0.0007 70
Type of cancer
Colorectal cancer 3 0.76 (0.64, 0.90) 0.78 0
Lung cancer 4 0.78 (0.70, 0.87) 0.53 0
Gastric cancer 4 0.83 (0.75, 0.92) < 0.0001 88
Liver cancer 3 0.82 (0.73, 0.91) 0.41 0
Breast cancer 1 0.71 (0.54, 0.92) d d
Hematologic 35372
malignancies
1 0.75 (0.55, 1.03) d d
Prostate cancer 1 0.88 (0.70, 1.10) d d
Fig. 6. Meta-analysis of studies examining association between ginseng consumption and risk of (A) colorectal cancer, (B) lung cancer, (C) gastric cancer, and (D) liver cancer. CI,
conﬁdence interval.
J Ginseng Res 2016;40:269e277276health relevance of such a relation. Previous epidemiological
studies have already identiﬁed several dietary and nutritional fac-
tors associated with the risk of various cancers, particularly those of
the digestive tract. This weighs in favor of the capability of epide-
miological studies included in this meta-analysis to assess the as-
sociation of cancer with ginseng consumption.5. Conclusion
To the best of our knowledge, this review is the ﬁrst to sys-
tematically perform a quantitative evaluation of the chemo-
preventive effect of ginseng on the incidence of cancer, addressing
the lack of this type of research. In summary, ginseng consumption
was associated with a signiﬁcantly lower risk of developing cancer.
However, the ﬁndings should be interpreted with caution due to
the low quality of the included trials. Rigorous multicenter, large-
scale clinical trials should be carried out to reveal the exact effec-
tiveness in the future.Conﬂicts of interest
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